Skip to main content

Institutional intelligence for Kerala Ayurveda Ltd

Cross-view mutual fund activity and super-investor shareholding · Jun 2026 SHP.

Tracked super investors holding ≥1%

Ownership breakdown

Estimated from named holders at or above 1% in the latest filing (Jun 2026). Official category totals not yet parsed. Sums to 75.91%.

  • Promoters35.60%
  • Retail & others (est.)40.31%
  • Super Investors 5.92%(subset)
  • 1% Club 18.17%(subset)

Super Investors and 1% Club names below are disclosed holders at or above 1%. They are subsets of the categories above, not additive.

Holder details (≥1% disclosed names)

1% Club — Individuals & others

Non-promoter ≥1% holders not matched to a curated profile

18.17%11 named
HolderStakeSharesValue (₹ Cr)
4.41%5,72,891₹10.4 Cr
1.85%2,40,500₹4.4 Cr
1.77%2,30,000₹4.2 Cr
1.60%2,08,470₹3.8 Cr
1.33%1,73,000₹3.1 Cr
1.33%1,72,671₹3.1 Cr
1.29%1,68,214₹3.1 Cr
1.17%1,52,444₹2.8 Cr
1.17%1,52,493₹2.8 Cr
1.15%1,50,050₹2.7 Cr
1.10%1,43,500₹2.6 Cr

Super Investors

Curated tracked investor profiles

5.92%2 named
HolderStakeSharesValue (₹ Cr)
3.41%4,43,063₹8.1 Cr
Tracked as Sanjiv Shah2.51%3,26,345₹5.9 Cr

Promoters

Promoter & promoter group

2 named
HolderStakeSharesValue (₹ Cr)
30.75%39,96,627₹72.7 Cr
4.85%6,30,000₹11.5 Cr

DII (other)

Insurance, banks, AIF, other domestic institutions

No names

No named holders ≥1% in this bucket.

FII / FPI

Foreign portfolio investors

No names

No named holders ≥1% in this bucket.

Mutual Funds

Domestic mutual funds & UTI

No names

No named holders ≥1% in this bucket.

Retail & others

Holders below 1% disclosure threshold and public non-institutions

SEBI requires naming only shareholders with ≥1% stake. The remaining includes retail investors, small HNIs, employee trusts, and other holders below the disclosure threshold — aggregated in the official filing.

Shareholding data sourced from NSE/BSE regulatory filings. Category chart uses official filing totals; named holder lists include every disclosed ≥1% position. Not investment advice. See our disclaimer and methodology.